Condition: HR+ Breast Cancer · Triple Negative Breast Cancer (TNBC) · CCNE1 Amplified Advanced Solid Tumors · Sponsor: NiKang Therapeutics, Inc.
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET * What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET
This description comes directly from the study's public registry record.
Sponsor Contact · 302-596-8654 · clinicaltrials@nikangtx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| SCRI Florida Cancer Specialists - Sarasota | Sarasota, Florida, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| South Texas Accelerated Research Therapeutics (START) Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07029399